Details of the Drug
General Information of Drug (ID: DM5SZHR)
| Drug Name |
6-amino-5-bromouracil
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
6312-73-8; 5-Bromo-6-aminouracil; 6-Amino-5-bromouracil; 6-Amino-5-bromopyrimidine-2,4(1H,3H)-dione; 6-Amino-5-bromo-1H-pyrimidine-2,4-dione; 6-amino-5-bromo-1,2,3,4-tetrahydropyrimidine-2,4-dione; CHEMBL64909; 6-amino-5-bromopyrimidine-2,4-diol; 6-amino-5-bromo-2,4(1H,3H)-pyrimidinedione; 6-amino-5-bromo-1,3-dihydropyrimidine-2,4-dione; NSC40394; EINECS 228-638-7; NSC 27652; NSC 40394; AC1Q24DM; AC1Q50HI; AC1L2ZP9; SCHEMBL2894070; CTK5B7686; KS-00001QBO; DTXSID60212460; MolPort-000-873-593; FSLBEEVCUZFKRL-UHFFFAOYSA-N
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 206 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -0.5 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


